alexa Macular Supplements Containing Zinc and Vitamin A Shoul
ISSN: 2329-6887

Journal of Pharmacovigilance
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Macular Supplements Containing Zinc and Vitamin A Should Be Replaced with Meso-Zeaxanthin, Lutein and Zeaxanthin: An Ophthalmic Need for Pharmacovigilance

Michael J Tolentino*
University of Central Florida, Center for Retina and Macular Disease, 250 Avenue K SW Suite 200, Winter Haven Florida 33803, USA
Corresponding Author : Michael J Tolentino
Associate Professor Ophthalmology
University of Central Florida
Center for Retina and Macular Disease
250 Avenue K SW Suite 200
Winter Haven Florida 33803, USA
Tel: 863 297 5400; 863 899 3509
E-mail: [email protected]
Received: January 18, 2016; Accepted: February 04, 2016; Published: February 08, 2016
Citation: Tolentino MJ (2016) Macular Supplements Containing Zinc and Vitamin A Should Be Replaced with Meso-Zeaxanthin, Lutein and Zeaxanthin: An Ophthalmic Need for Pharmacovigilance. J Pharmacovigil 4:195. doi:10.4172/2329-6887.1000195
Copyright: © 2016 Tolentino MJ. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
 

Abstract

Objective: The objective of this paper is to report the importance of ophthalmic pharmacovigilance in AREDS macular formulations due to the potential toxicity of these macular vitamins with minimal benefit for patients with advanced exudative macular degeneration.

Background: Age Related Eye Disease Studies macular formulations are currently treated as nutritional supplements and as such, do not undergo the required evaluation process for toxicity as pharmacologic agents. However, they more closely resemble a pharmacologic agent rather than a true nutritional supplement.

Results: Macular formations have minimal benefit for patients with advanced exudative age-related macular degeneration and contain unsafe doses of substances like beta-carotene and zinc, which have the potential to cause cancer, Alzheimer’s disease, and worsen macular degeneration. This potential for toxicity necessitates pharmacovigilance for macular supplements to prevent exposure to harmful substances for negligible gain.

Conclusion: These supplements should be replaced with other compounds that have both macular protective properties and an excellent safety profile such as Meso-Zeaxanthin, lutein and zeaxanthin.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords